噬菌体表面展示肽库技术在病毒研究中的应用

噬菌体表面展示肽库技术是近年来发展起来的用丝状噬菌体展示外源肽的一项新技术,被广泛应用于分子识别的各个领域。本文就该技术在病毒受体、病毒抗原表位、病毒抗体以及病毒疫苗和病毒性疾病的诊断等央电荷和一简要概述。     

噬菌体展示肽库在细胞信号转导研究中的应用

细胞信号转导是一个由信号分子相互作用介导的生物信息传递的过程 ,蛋白质之间以及蛋白质与其他分子间的相互作用是信号转导的基础。近年来 ,利用噬菌体展示肽库技术研究细胞信号转导 ,取得了很多有意义的结果。1.鉴定信号蛋白识别结合位点信号蛋白之间特异性的识别结合主要通过一小段保守区实现 ,如ＳＨ2区 (Ｓｒｃ ｈｏｍｏｌｏｇｙｄｏｍａｉｎ)、ＳＨ3区、ＰＴＢ区 (ｐｈｏｓｐｈｏｔｙｒｏｓｉｎｅ ｂｉｎｄｉｎｇｄｏｍａｉｎ)等。用噬菌体展示肽库技术可以快速获得与这些保守区结合的配体的结构信息。用Ｓｒｃ酪氨酸激酶的ＳＨ3区筛…     

噬菌体展示肽文库及其应用

肽库是研究与特定靶分子高亲和结合配体的有力工具,肽文库可被分为合成文库和噬菌体肽文库两类,作者综述了噬菌体肽文库及其蛋白质结构域分析定位,疫苗研制及抗原表位分析和药物设计等方面的应用。     

噬菌体展示肽在血管导向治疗方面的应用

介绍了一种利用噬菌体肽库的新技术－体内噬菌体展示（n vivo phage display)。这项技术是在活的动物体内进行的肽库筛选。将肽库通过静脉注射到动物体内,因为血管分子内皮的异质性,噬菌体可以选择性地导向不同组织,这样就可以筛到与特定组织特异结合的噬菌体展示肽。动物实验表明,前凋亡小肽和细胞毒素与导各肽偶联后 治疗效果。这项技术应用于临床,一定有助于肿瘤等疾病的导向治疗和造影技术的发展。     

噬菌体展示定位和噬菌体展示工程

噬菌体展示是指将外源基因克隆到丝状噬菌体ｆｄ染色体ＤＮＡ上,然后以融合白 形式展示了于噬菌体衣壳蛋白表面的技术。本文将概述丝状噬菌体展示技术的最新进展,特别是表位定位的原理及其应用,可包括以下三部分：１．比较几种不同噬菌体展示策略的技术原理;２．展示表位的重组噬菌体在诊断试剂上的开发价值;３．展示表位的重组噬菌体在疫备研究上的应用前景。     

噬菌体肽库技术

80年代中期,George P.Smith在前人对丝状噬菌体分子生物学研究的基础上首先提出了噬菌体展示技术(Phage Display),其核心就是将蛋白质分子的表型和基因型巧妙地结合于丝状噬菌体这样一个便于对其进行一系列生化和遗传操作的载体上,从而大大简化了蛋白质分子表达库的筛选和鉴定。基于这一优点,噬菌     

噬菌体展示文库及其应用

近十几年来,噬菌体展示技术得到了迅速的发展。通过展示随机肽库可用来筛选与特殊靶分子相结合的配基;模拟非蛋白的配基;也可用作确定抗体表位的工具。展示蛋白;或其功能结构的文库为我们提供了分析结构与功能关系的体系,并能产生具有改变结合位点或新的催化活性的蛋白。展示短的抗原决定簇的融合噬菌体为开发新的疫苗提供了基础,而表达抗体片段的文库则提供了一种产生单克隆抗体的方法。     

噬菌体展示技术的发展及应用

噬菌体展示技术是一种用于筛选和改造功能性多肽的生物技术 ,编码多肽的ＤＮＡ片段与噬菌体表面蛋白的编码基因融合后 ,以融合蛋白的形式在噬菌体的表面表达出多肽序列。这是一种表型与基因型的统一。噬菌体展示技术最初是以Ｍ 13噬菌体为载体的 ,其宿主菌为大肠杆菌。以大肠杆菌为宿主的展示系统还有其他 ,如λ噬菌体和Ｔ4噬菌体等展示系统。还有利用真核细胞的病毒以及酵母菌作为展示系统的。这些展示系统各有各的优势 ,但最常用的仍是Ｍ 13噬菌体表达系统。最初的噬菌体展示系统是将外源肽或蛋白质与噬菌体外壳蛋白ＰⅢ或ＰⅧ的Ｎ末端融…     

噬菌体展示技术在疫苗研究中的应用进展

噬菌体是一种以细菌为宿主的具有严格宿主特异性的病毒,近年来由于分子生物学和基因重组技术的长足发展,藉助噬菌体的基本特性创立和发展了噬菌体展示技术,此项技术将外源肽或蛋白与特定噬菌体衣壳蛋白融合并展示于噬菌体表面。利用这项技术制作的疫苗具有安全可靠、稳定性高、免疫效果好等优点,因此,在新型疫苗的研制上具有很大的应用价值。就噬菌体展示技术及其在疫苗研究中的优势、预防性疫苗与治疗性疫苗的研究进展予以综述。     

噬菌体展示技术及其在肿瘤研究中的应用

噬菌体表面展示技术是一项特异性多肽或蛋白的筛选技术,它将随机序列的多肽或蛋白片段与噬菌体衣壳蛋白融合表达而呈现于病毒表面,被展示的多肽能保持相对独立的空间结构,使其能够与配体作用而达到模仿性筛选特异性分子表位,从而提供了高通量高效率的筛选系统。近年来噬菌体展示技术已广泛应用于肿瘤抗原抗体库的建立、单克隆抗体制备、多肽筛选、疫苗研制、肿瘤相关抗原筛选和抗原表位研究、药物设计、癌症检测和诊断、基因治疗及细胞信号转导研究等。就近年来噬菌体展示技术在肿瘤相关研究中的运用作以综述。     

神经药物通过血脑屏障的有关研究

随着世界人口老龄化的日趋加快 ,神经系统的疾病正日益成为威胁人类健康的主要问题。尽管新的神经药物已经能够治疗多种神经疾病 ,但是血脑屏障的存在使 95%的药物不能从血液进入脑部[1] 。未来神经疾病的治疗只有通过中枢神经系统 (ＣＮＳ)药物的发明和ＣＮＳ药物的传送两方面同时获得发展才能够取得突破。ＣＮＳ药物传送所面临的问题在于如何使药物有效的通过血脑屏障 (ｂｌｏｏｄｂｒａｉｎＢａｒｒｉ ｅｒ,ＢＢＢ)。1 .血脑屏障的结构与功能血脑屏障由脑毛细血管内皮细胞、基膜和神经胶质膜构成。脑部血循环的毛细血管内皮细胞相互接触…     

Protein Kinase D Promotes Airway Epithelial Barrier Dysfunction and Permeability through Down-regulation of Claudin-1

At the interface between host and external environment, the airway epithelium serves as a major protective barrier. In the present study we show that protein kinase D (PKD) plays an important role in the formation and integrity of the airway epithelial barrier. Either inhibition of PKD activity or silencing of PKD increased transepithelial electrical resistance (TEER), resulting in a tighter epithelial barrier. Among the three PKD isoforms, PKD3 knockdown was the most efficient one to increase TEER in polarized airway epithelial monolayers. In contrast, overexpression of PKD3 wild type, but not PKD3 kinase-inactive mutant, disrupted the formation of apical intercellular junctions and their reassembly, impaired the development of TEER, and increased paracellular permeability to sodium fluorescein in airway epithelial monolayers. We further found that overexpression of PKD, in particular PKD3, markedly suppressed the mRNA and protein levels of claudin-1 but had only minor effects on the expression of other tight junctional proteins (claudin-3, claudin-4, claudin-5, occludin, and ZO-1) and adherent junctional proteins (E-cadherin and β-catenin). Immunofluorescence study revealed that claudin-1 level was markedly reduced and almost disappeared from intercellular contacts in PKD3-overexpressed epithelial monolayers and that claudin-4 was also restricted from intercellular contacts and tended to accumulate in the cell cytosolic compartments. Last, we found that claudin-1 knockdown prevented TEER elevation by PKD inhibition or silencing in airway epithelial monolayers. These novel findings indicate that PKD negatively regulates human airway epithelial barrier formation and integrity through down-regulation of claudin-1, which is a key component of tight junctions.     

Identification of a Conserved B-cell Epitope on Reticuloendotheliosis Virus Envelope Protein by Screening a Phage-displayed Random Peptide Library

Background

The gp90 protein of avian reticuloendotheliosis-associated virus (REV-A) is an important envelope glycoprotein, which is responsible for inducing protective antibody immune responses in animals. B-cell epitopes on the gp90 protein of REV have not been well studied and reported.

Methods and Results

This study describes the identification of a linear B-cell epitope on the gp90 protein by screening a phage-displayed 12-mer random peptide library with the neutralizing monoclonal antibody (mAb) A9E8 directed against the gp90. The mAb A9E8 recognized phages displaying peptides with the consensus motif SVQYHPL. Amino acid sequence of the motif exactly matched ²¹³SVQYHPL²¹⁹ of the gp90. Further identification of the displayed B cell epitope was conducted using a set of truncated peptides expressed as GST fusion proteins and the Western blot results indicated that ²¹³SVQYHPL²¹⁹ was the minimal determinant of the linear B cell epitope recognized by the mAb A9E8. Moreover, an eight amino acid peptide SVQYHPLA was proven to be the minimal unit of the epitope with the maximal binding activity to mAb A9E8. The REV-A-positive chicken serum reacted with the minimal linear epitopes in Western blot, revealing the importance of the eight amino acids of the epitope in antibody-epitope binding activity. Furthermore, we found that the epitope is a common motif shared among REV-A and other members of REV group.

Conclusions and Significance

We identified ²¹³SVQYHPL²¹⁹ as a gp90-specific linear B-cell epitope recognized by the neutralizing mAb A9E8. The results in this study may have potential applications in development of diagnostic techniques and epitope-based marker vaccines against REV-A and other viruses of the REV group.     

CNS Drug Design Based on Principles of Blood-Brain Barrier Transport

Abstract: Lipid-soluble small molecules with a molecular mass under a 400–600-Da threshold are transported readily through the blood-brain barrier in vivo owing to lipid-mediated transport. However, other small molecules lacking these particular molecular properties, antisense drugs, and peptide-based pharmaceuticals generally undergo negligible transport through the blood-brain barrier in pharmacologically significant amounts. Therefore, if present day CNS drug discovery programs are to avoid termination caused by negligible blood-brain barrier transport, it is important to merge CNS drug discovery and CNS drug delivery as early as possible in the overall CNS drug development process. Strategies for special formulation that enable drug transport through the blood-brain barrier arise from knowledge of the molecular and cellular biology of blood-brain barrier transport processes.     

讲座细胞药物的制备工艺——细胞药物连载之二

细胞药物制备的质量直接关系到细胞治疗的效果。由于细胞治疗所用细胞是具有生物学效应的,细胞药物的制备技术和应用方案具有多样性、复杂性和特殊性,不像一般生物药物那样有统一的制作标准。细胞药物的制备过程主要包括供者筛查、供者检测、采集、加工、分离纯化、储存等,以造血干细胞、间充质干细胞、肝细胞及树突状细胞为例对其进行简要介绍。     

三氧化二砷脂质体透过载瘤大鼠血脑屏障的实验研究

目的：观察三氧化二砷（As2O3）脂质体通过载瘤大鼠血脑屏障（BBB）的效果。方法：超声薄膜分散法制备三氧化二砷脂质体,建立药物标准曲线,检测包封率;立体定向技术建立C6／Wistar大鼠脑胶质瘤模型;取Wistar雄性载瘤大鼠84只,随机分为三氧化二砷脂质体组和三氧化二砷组,分别经静脉注射三氧化二砷脂质体和三氧化二砷注射液,给药后0．5h、1h、2h、4h、8h、16h、24h取大鼠脑组织冻存,应用双道原子荧光法检测载瘤大鼠脑组织中的砷含量。结果：制备稳定的三氧化二砷脂质体,包封率分别为92、2％,92．2％,92．3％;As2O3脂质体组及As2O3给药后7个时间点鼠脑组织中砷含量（μg／L）分别为：341．09±18．18,523、98±27．36,475．19±15、52,467.02±22．46,471．52±24．38,382.30±13．26,282．47±19．71;99.93±17.10,148.07±26、21,101.78±17．54,89．09±19．41,74.39±13．85,50．44±15.31,51．52±19．23。比较给三氧化二砷组及给三氧化二砷脂质体组载瘤大鼠脑组织中砷含量有显著差异（P〈0．05）。结论：三氧化二砷脂质体对血脑屏障的透过性明显优于单纯砷剂。     

金纳米粒在药物传递系统中的应用

金纳米粒是一种新型纳米载体,具有独特的理化、光学和生物学性质,且具有低毒性、低免疫原性、生物相容性好、体表面积大、易制备、粒径和形态可控、表面易修饰等优点,在生物医学领域和药物传递系统中具有广阔的应用前景。综述金纳米粒在小分子药物和基因药物传递系统中的应用研究新进展。     

Effect of Vitamin E on Blood-Brain Barrier Permeability in Aged Rats with PTZ-Induced Convulsions

The effect of vitamin E on blood-brain barrier (BBB) permeability was studied under conditions of pentylenetetrazole (PTZ)-induced convulsions in aged (23- to 24-month-old) male albino rats; Evans Blue was used as a tracer. The BBB permeability was found to increase considerably in rats with PTZ-evoked seizures; the Evans Blue contents in the left and right hemispheres and cerebellum + brainstem region were significantly higher than those in the control. Vitamin E at a dose of 70 mg/kg exerted practically no beneficial effect on the increased BBB permeability in rats with seizures, while a greater dose of vitamin E (700 mg/kg) exerted a significant protective effect, especially with respect to the cerebellum + brainstem regions (P < 0.01). The seizure-related rise in the arterial blood pressure was also smaller in the latter experimental group. Thus, our observations confirm the importance of the vitamin E dose as a protective factor for BBB permeability and demonstrate that the dose dependence of this antioxidant in aged animals differs from that in younger organisms.     

Effect of Diabetes Mellitus on the Permeability of the Blood–Brain Barrier to Insulin

Banks, W. A., J. B. Jaspan and A. J. Kastin. Effect of diabetes mellitus on the permeability of the blood–brain barrier to insulin. Peptides 18(10) 1577–1584, 1997.—Insulin derived from the peripheral circulation has been shown to exert various effects on the brain due to its ability to cross the blood–brain barrier (BBB). The relation between diabetes mellitus and insulin has been extensively studied for peripheral tissues but not for central nervous system tissues. We examined the effects that streptozotocin- or alloxan-induced diabetes have on the transport of insulin across the murine BBB. We used multiple-time regression analysis to measure the unidirectional influx rate constant (K_i) and vascular association (V_i) of intravenously injected, radioactively labeled human insulin (I-Ins). Treatment with streptozotocin induced an enhancement of both the K_i and V_i of I-Ins that correlated with the onset of diabetes. Brain perfusion showed that the enhanced uptake was not due to altered vascular space or levels of insulin in the serum. Alloxan enhanced K_i and V_i after 5 days but the early phase of diabetes was associated with a decreased K_i. Hyperglycemia induced by the intraperitoneal injection of glucose elevated the V_i but abolished the K_i. Furthermore, altered I-Ins uptake by brain was not associated with changes in brain or body weight. These results show that there is an increased uptake of I-Ins by the brain in the diabetic state that is not due to acute changes in the serum levels of glucose or insulin, altered vascular space, or catabolic events. Chronic changes in levels of glucose, insulin or other hormone or neuroendocrine agents are likely to underlie the altered rate of transport of insulin across the BBB of diabetic mice.